Lyell Immunopharma
LYEL
120 hedge funds and large institutions have $194M invested in Lyell Immunopharma in 2024 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 34 increasing their positions, 45 reducing their positions, and 21 closing their positions.
21% more call options, than puts
Call options by funds: $17K | Put options by funds: $14K
0.01% more ownership
Funds ownership: 2.61% → 2.62% (+0.01%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
6% less funds holding
Funds holding: 127 → 120 (-7)
24% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 21
24% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 45
35% less capital invested
Capital invested by funds: $297M → $194M (-$103M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$14.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.72M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$1.78M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.25M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$875K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$4.01M |
| 2 |
Millennium Management
New York
|
-$2.92M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$2.29M |
| 4 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
-$1.94M |
| 5 |
JP Morgan Chase
New York
|
-$1.33M |
LYEL Hedge Fund Activity: Q2 2024 in Review
120 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q2 2024, worth a combined $194M — down 35% from $297M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of LYEL and 16 opened new positions — a net loss of 5 holders — while 45 trimmed existing stakes and 34 added.
The largest buyer was OrbiMed, adding an estimated $14.8M. The largest seller was Opaleye Management, cutting an estimated $4.01M.
- 120 institutional investors held Lyell Immunopharma (LYEL) as of Q2 2024, down from 127 in Q1 2024.
- Funds reported $194M of Lyell Immunopharma stock for Q2 2024, down 35% quarter-over-quarter.
- 16 funds opened new Lyell Immunopharma positions in Q2 2024 and 21 closed out, a net change of -5 holders.
- The largest Lyell Immunopharma buyer in Q2 2024 was OrbiMed, an estimated $14.8M added.
- The largest Lyell Immunopharma seller in Q2 2024 was Opaleye Management, an estimated $4.01M sold.
Based on aggregated 13F filings for Q2 2024.